MitoSkin

Enabled by next-gen transdermal delivery technology, MitoSkin formulations work by targeting reactive oxygen species, membrane instability, and mitochondrial dysfunction. These subcellular pathologies reduce the body's ability to recover from disease and environmental stressors contributing to chronic illness and inflammation. Addressing these problems is key for maintaining young and healthy cells. Solutions that don't address these problems are simply covering them up. Enterprise services in: NAD+ Precursor Systemic Delivery Liposomal Delivery Polymer Drug Loading Non-occlusive Transdermal Delivery Mitochondria Density Augmentation Microcavity Encapsulation Raw Material Sourcing and Processing

Website

http://mitoskin.org

External link for MitoSkin

Industry

Biotechnology

Company size

2-10 employees

Headquarters

Chicago, IL

Type

Privately Held

Founded

2021